Clopidogrel Found More Effective Than Aspirin for Long-Term Antiplatelet Therapy After Coronary Stent Implantation

A recent study has found that clopidogrel outperforms aspirin as a long-term antiplatelet therapy for patients at high risk of recurrent cardiovascular events following coronary stent implantation. The research, conducted by a team from the Division of Cardiology at Samsung Medical Center, Sungkyunkwan University School of Medicine, and Samsung Changwon Hospital, highlights clopidogrel’s effectiveness in reducing the likelihood of adverse cardiovascular outcomes compared to aspirin.

The study was led by Professors Joo-Yong Hahn, Young Bin Song, and Ki Hong Choi from Samsung Medical Center, alongside Professor Yong Hwan Park from Samsung Changwon Hospital. The findings suggest that clopidogrel may offer better protection for individuals who have undergone coronary stenting and are considered at elevated risk for recurring heart-related complications. Researchers focused on comparing the two medications’ efficacy in preventing further cardiovascular events over an extended period.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: February 5, 2026

Author

GOAI